companydata.dkcompanydata.dk

VELOXIS PHARMACEUTICALS A/S: Financial statements 2021

CVR: 26527767

Source: annual report 2021, Danish Business Authority

01/04/2020 – 31/03/2021

VELOXIS PHARMACEUTICALS A/S (CVR 26527767) has filed annual accounts for 2021. In 2021, the company reported revenue of USD 45,335,000 and a net result of USD 1,057,461,000. The profit margin was 2,332.5%. Equity in the 2021 report amounted to USD 1,303,915,000. The solvency ratio was 100%.

Revenue
USD 45,335,000
Gross Profit
USD 45,335,000
Profit/Loss
USD 1,057,461,000
Equity
USD 1,303,915,000
Total Assets
USD 1,304,141,000

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
202145.3M USD45.3M USD1.1B USD1.3B USD-
201839.5M USD31.6M USD-5.3M USD4.6M USD-
201730.2M USD25M USD-9.5M USD5.3M USD-
20169.2M USD6.2M USD-10.1M USD10.2M USD-
201514.2M-989K-176.1M89.7M-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Find more companies like VELOXIS PHARMACEUTICALS A/S

Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.

Try the lead list generator

Events in 2021

Mark Earl Hensley joins VELOXIS PHARMACEUTICALS A/S as adm. dir.Nov 8, 2021

As of November 8, 2021, Mark Earl Hensley is registered as adm. dir. of VELOXIS PHARMACEUTICALS A/S.

Craig Alexander Collard steps down as adm. dir. of VELOXIS PHARMACEUTICALS A/SNov 8, 2021

As of November 8, 2021, Craig Alexander Collard has stepped down as adm. dir. of VELOXIS PHARMACEUTICALS A/S.

Ira Duarte steps down as director of VELOXIS PHARMACEUTICALS A/SNov 8, 2021

As of November 8, 2021, Ira Duarte has stepped down as director of VELOXIS PHARMACEUTICALS A/S.

Hideo Hikami joins the board of VELOXIS PHARMACEUTICALS A/SApr 14, 2021

As of April 14, 2021, Hideo Hikami has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.

Hiroki Ideguchi joins the board of VELOXIS PHARMACEUTICALS A/SApr 14, 2021

As of April 14, 2021, Hiroki Ideguchi has joined the board of directors of VELOXIS PHARMACEUTICALS A/S.

Masaya Etoh leaves the board of VELOXIS PHARMACEUTICALS A/SApr 14, 2021

As of April 14, 2021, Masaya Etoh has left the board of directors of VELOXIS PHARMACEUTICALS A/S.

Matthew Ryan Dumont leaves the board of VELOXIS PHARMACEUTICALS A/SApr 14, 2021

As of April 14, 2021, Matthew Ryan Dumont has left the board of directors of VELOXIS PHARMACEUTICALS A/S.

Registered as owner of VELOXIS PHARMACEUTICALS A/SJan 4, 2021

As of January 4, 2021, is registered as an owner of VELOXIS PHARMACEUTICALS A/S with an ownership share of 100%.

About VELOXIS PHARMACEUTICALS A/S

VELOXIS PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2002. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named LIFECYCLE PHARMA A/S and PHAROTECH A/S. The management consists of Daisuke Matsuo. The board consists of Keigo Nakatsukasa (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. The company has 1 employee (2022). In 2026, the company reported a net result of DKK -1,553,000. Equity in the 2026 report amounted to DKK 611,587,000.

Source: annual report 2026, Danish Business Authority